All In Biotech

Drug Trial Radar · NCT05769777

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

999

Actual

Start

Apr 3, 2023

Primary completion

Jun 11, 2031

Study completion Jun 11, 2031

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD). The purpose of this study is to characterize the long-term safety and efficacy of amlitelimab in treated participants with age ≥12 years old with moderate to severe AD. The study duration per participant will be up to 284 weeks, including: * A screening period of up to 2 to 4 weeks * An open label treatment period of up to 268 weeks (approximately 5 years) * A post-treatment safety follow-up period of at least 20 weeks after the last dose administration (last IMP administration at Week 264) The planned number of visits will be 35 visits.

Conditions

  • Dermatitis Atopic

Interventions

  • AmlitelimabDrug

    Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline up to end of study (EOS) (Week 284)
  2. Percentage of participants who experienced Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: Baseline up to EOS (Week 284)

Locations

174 sites in 25 countries. Site status is shown where the registry gives one.

  • Allervie Clinical Research - Birmingham- Site Number : 8400050

    Birmingham, Alabama

  • Research Solutions of Arizona- Site Number : 8400020

    Litchfield Park, Arizona

  • Dermatology Trial Associates- Site Number : 8400027

    Bryant, Arkansas

  • University Dermatology Trials- Site Number : 8400052

    Newport Beach, California

  • Children's Hospital Colorado - Aurora- Site Number : 8400041

    Aurora, Colorado

  • IMMUNOe International Research Centers - Centennial- Site Number : 8400024

    Centennial, Colorado

  • Renaissance Research and Medical Group- Site Number : 8400006

    Cape Coral, Florida

  • Florida Pharmaceutical Research and Associates- Site Number : 8400018

    Miami, Florida

  • Miami Clinical Research Tower- Site Number : 8400036

    Miami, Florida

  • Florida Research Center- Site Number : 8400011

    Miami, Florida

  • Clinical Research Trials of Florida- Site Number : 8400054

    Tampa, Florida

  • Advanced Medical Research - Atlanta- Site Number : 8400044

    Atlanta, Georgia

  • Georgia Skin & Cancer Clinic- Site Number : 8400048

    Savannah, Georgia

  • Sneeze Wheeze & Itch Associates- Site Number : 8400002

    Normal, Illinois

  • Kentucky Advanced Medical Research- Site Number : 8400014

    Murray, Kentucky

  • The Derm Institute of West Michigan- Site Number : 8400043

    Caledonia, Michigan

  • Michigan Dermatology Institute - Livonia- Site Number : 8401010

    Livonia, Michigan

  • Michigan Dermatology Institute - Waterford- Site Number : 8400010

    Waterford, Michigan

  • Dermatology Research Center of Oklahoma- Site Number : 8400035

    Tulsa, Oklahoma

  • The Children's Hospital of Philadelphia- Site Number : 8400009

    Philadelphia, Pennsylvania

  • Texas Dermatology and Laser Specialists - San Antonio - Oakwell Court- Site Number : 8400053

    San Antonio, Texas

  • Private Practice - Dr. Marthe N. Dika- Site Number : 8400022

    Burlington, Wisconsin

  • Investigational Site Number : 0320008

    Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Buenos Aires, Argentina

  • Investigational Site Number : 0320009

    Buenos Aires, Argentina

  • Investigational Site Number : 0320005

    Buenos Aires, Argentina

  • Investigational Site Number : 0320022

    General Pico, La Pampa Province, Argentina

  • Investigational Site Number : 0320006

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0320007

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0360002

    Kogarah, New South Wales, Australia

  • Investigational Site Number : 0360001

    Sydney, New South Wales, Australia

  • IDERJ - Instituto de Dermatologia e Estética do Brasil- Site Number : 0760004

    Rio de Janeiro, Brazil

  • Centro de Pesquisas da Clínica IBIS- Site Number : 0760002

    Salvador, Estado de Bahia, Brazil

  • Hospital de Clinicas da Universidade Federal do Parana- Site Number : 0760022

    Curitiba, Paraná, Brazil

  • Pontifica Universidade Catolica do Parana- Site Number : 0760023

    Curitiba, Paraná, Brazil

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760005

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760008

    Ribeirão Preto, São Paulo, Brazil

Showing 40 of 174 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.